US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ballast Small/Mid Cap ETF

37.77

+0.59001.59%

Post-market: 37.770.00000.00%16:05 EDT

Volume:6.89K

Turnover:260.17K

Market Cap:147.30M

PE:- -

High:37.91

Open:37.36

Low:37.36

Close:37.18

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

GEO Q4 Earnings: Sales Beat, EPS Miss, New Immigration Contract And More

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MGMT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MGMT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MGMT\",,,,,undefined,":{"symbol":"MGMT","market":"US","secType":"STK","nameCN":"Ballast Small/Mid Cap ETF","latestPrice":37.77,"timestamp":1746734400000,"preClose":37.18,"halted":0,"volume":6886,"hourTrading":{"tag":"盘后","latestPrice":37.77,"preClose":37.77,"latestTime":"16:05 EDT","volume":2,"amount":75.54,"timestamp":1746734709758},"delay":0,"floatShares":3900000,"shares":3900000,"eps":0,"marketStatus":"Post-Mkt","change":0.59,"latestTime":"05-08 17:32:53 EDT","open":37.36,"high":37.91,"low":37.36,"amount":260169.6186,"amplitude":0.014793,"askPrice":44.49,"askSize":100,"bidPrice":30.92,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":37.18,"sharesOutstanding":3900000,"nav":37.21,"aum":145116585.39,"dividendRate":0.00556,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.77,"preClose":37.77,"latestTime":"16:05 EDT","volume":2,"amount":75.54,"timestamp":1746734709758},"volumeRatio":0.676092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MGMT\",,,,,undefined,":{"symbol":"MGMT","floatShares":3900000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.676092,"shares":3900000,"dividePrice":0.21,"high":37.91,"amplitude":0.014793,"preClose":37.18,"low":37.36,"week52Low":32.09,"pbRate":"--","week52High":44.5,"institutionHeld":0,"latestPrice":37.77,"eps":0,"divideRate":0.00556,"volume":6886,"delay":0,"ttmEps":0,"open":37.36,"prevYearClose":41.5849,"prevWeekClose":37.8,"prevMonthClose":36.82,"prevQuarterClose":38.6,"fiveDayClose":37.03,"twentyDayClose":36.32,"sixtyDayClose":42.0924},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MGMT\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MGMT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533958210","title":"GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2533958210","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533958210?lang=en_us&edition=fundamental","pubTime":"2025-05-07 23:32","pubTimestamp":1746631947,"startTime":"0","endTime":"0","summary":"GEO Group reported lower Q1 revenue and adjusted EBITDA, missing consensus. EPS also fell short. Outlook raised for FY25 but Q2 expectations lowered.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45258853/geo-missed-q1-targets-on-rising-costs-and-debt-guides-q2-below-street-estimates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4547","BOUT","BK4165","MGMT","BK4084","GEO","BK4516","BK4585"],"gpt_icon":0},{"id":"2524186551","title":"Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2524186551","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524186551?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:01","pubTimestamp":1743508860,"startTime":"0","endTime":"0","summary":"Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of careNEEDHAM, Mass., April  01, 2025  (GLOBE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053320/0/en/Candel-Therapeutics-Announces-Publication-of-Phase-1b-Clinical-Trial-Data-on-the-Combination-of-CAN-2409-and-Nivolumab-plus-Standard-of-Care-in-Newly-Diagnosed-High-Grade-Glioma-Pa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4526","BK4595","L","BK4139","BK4107","BK4124","BK4585","LU0053666078.USD","MGMT","SMP","BK4600","BK4170","CADL","BK4588","LENZ"],"gpt_icon":1},{"id":"2517154408","title":"Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154408","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154408?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment. Fully funded by the U.S. Veterans’ Administration Special Emphasis Panel on Precision Oncology. Trial builds on promising clinical evidence supporting a PARP inhibitor and temozolomide combination in Small Cell Lung Cancer. Boston —Allarity Therapeutics, Inc.  , a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating chemotherapy agent, for the treatment of recurrent Small Cell Lung Cancer . The trial is fully funded by the U.S. Veterans Administration  through the Special Emphasis Panel on Precision Oncology and is being led by the VA and Academic Medical Oncologists at Indianapolis and Pittsburgh VA Medical Centers.Thomas Jensen, CEO of Allarity Therapeutics, stat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allarity-therapeutics-announces-phase-2-130000563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLR","LENZ","MGMT","BK4139"],"gpt_icon":0},{"id":"2514807160","title":"GEO Q4 Earnings: Sales Beat, EPS Miss, New Immigration Contract And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807160","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514807160?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:44","pubTimestamp":1740663853,"startTime":"0","endTime":"0","summary":"The GEO Group reported lower adjusted EBITDA and EPS for Q4 2024, but surpassed revenue expectations. FY25 outlook is below consensus, but company plans to reduce debt and has secured a $1 billion contract with ICE for its Delaney Hall facility.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44005789/geo-q4-earnings-sales-beat-eps-miss-new-immigration-contract-and-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FNDA","MGMT","GEO"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MGMT\",params:#limit:5,,,undefined,":[{"date":"2024-12-30","symbol":"MGMT","amount":0.2138,"announcedDate":"2024-12-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Ballast Small/Mid Cap ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-06","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2025-01-06"},{"date":"2023-12-28","symbol":"MGMT","amount":0.43,"announcedDate":"2023-12-27","type":"dividend","market":"US","newRecordDate":"2023-12-29","defaultRemindTime":1703773800000,"name":"Ballast Small/Mid Cap ETF","recordDate":"2024-01-03","payableDate":"2023-12-29","currency":"USD","dateTimestamp":1703739600000,"payDate":"2024-01-03"},{"market":"US","date":"2022-12-29","symbol":"MGMT","amount":0.2859,"defaultRemindTime":1672324200000,"name":"Ballast Small/Mid Cap ETF","recordDate":"2023-01-05","payableDate":"2022-12-30","currency":"USD","type":"dividend","dateTimestamp":1672290000000},{"market":"US","date":"2021-12-30","symbol":"MGMT","amount":0.0964,"defaultRemindTime":1640874600000,"name":"Ballast Small/Mid Cap ETF","recordDate":"2022-01-05","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MGMT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-05","value":0.0964,"currency":"USD"},{"executeDate":"2022-12-29","recordDate":"2022-12-30","paymentDate":"2023-01-05","value":0.2859,"currency":"USD"},{"executeDate":"2023-12-28","recordDate":"2023-12-29","paymentDate":"2024-01-03","value":0.43,"currency":"USD"},{"executeDate":"2024-12-30","recordDate":"2024-12-30","paymentDate":"2025-01-06","value":0.2138,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MGMT\",market:\"US\",delay:false,,,undefined,":{}}}